|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.05 USD | -1.35% |
|
+5.59% | +24.13% |
| 07-24 | Wedbush Adjusts Price Target on NovoCure to $20 From $18, Maintains Neutral Rating | MT |
| 07-23 | NovoCure Limited, Q2 2026 Earnings Call, Jul 23, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bullish | Bullish |
| Resistance | 17.72 | 19.99 | 17.96 |
| Spread/Res. | -9.42% | -19.71% | -10.63% |
| Spread/Supp. | +8.15% | +17.93% | +17.41% |
| Support | 14.84 | 13.61 | 13.67 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- NVCR Stock
- Charts NovoCure Limited
Select your edition
All financial news and data tailored to specific country editions
